TCT-847 Everolimus-eluting bioresorbable scaffold for the treatment of coronary in-stent restenosis: immediate and 12 months clinical results

Background Treatment of patients with in-stent restenosis (ISR) remains a clinical and technical challenge. Everolimus-eluting bioresorbable scaffold (BRS) represent an attractive alternative for ISR treatment since long-term accumulation of several layers of metal within the vessel wall is avoided.

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B342-B342
Main Authors: Gomez-Blazquez, Ivan, Diaz, Victor Jimenez, Fernandez-Barbeira, Saleta, Fernández, Guillermo Bastos, De Miguel Castro, Antonio, Baz Alonso, Jose Antonio, Saez, Alberto Ortiz, Iñiguez, Andres
Format: Article
Language:English
Subjects:
Biocompatibility
Biomedical materials
Cardiology
Implants
Inhibitor drugs
Patients
Restenosis
Stents
Surgical implants
Thrombosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Treatment of patients with in-stent restenosis (ISR) remains a clinical and technical challenge. Everolimus-eluting bioresorbable scaffold (BRS) represent an attractive alternative for ISR treatment since long-term accumulation of several layers of metal within the vessel wall is avoided.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.1055